Tag: Lispro
ADOCIA announces the positive results of a Phase 1 study on BioChaperone® Lispro with its partner Tonghua Dongbao – 2022-12-29 at 08:00
• Adocia’s partner, Tonghua Dongbao, announced that the primary endpoint of this Phase 1 study has been met and that the results confirmed an accelerated profile of BioChaperone® Lispro compared…
Adocia announces the positive results of a study on BioChaperone Lispro – 29/12/2022 at 08:38
(AOF) – Adocia, a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces new positive…
ADOCIA announces the dosage of the first patient in the Phase 3 program of BioChaperone® Lispro with its partner Tonghua Dongbao – 05/09/2022 at 09:00
• A first patient has been dosed as part of this large phase 3 program involving 1,300 people with type 1 or 2 diabetes in 100 clinical research centers in…
The value of the day in Paris – Adocia: launch of a phase 3 with ultra-rapid insulin BC Lispro in China – 05/09/2022 at 09:36
(AOF) – Adocia jumped 5.7% to 4.65 euros. The biotech announced the dosing of the first patient in BioChaperone Lispro’s Phase 3 program with partner Tonghua Dongbao. BC Lispro belongs…